Identifying Genetic Subtypes May Aid Future Treatment Decisions in Lymphoma
Although the findings need to be tested further in clinical trials, this could lead to new targeted therapies with fewer toxicities for patients.
All articles by Katie Wilkerson
HIV-Associated Cancers: A Paradigm Shift?
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
Should the General Population Be Screened for MGUS?
Still unresolved is whether to screen the general population for MGUS, a largely asymptomatic condition usually noted during routine blood testing.
Can Understanding the Gut Microbiome Improve Clinical Oncology?
Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.
Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?
While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.
Cryosurgery: The Future of Breast Cancer Treatment?
Whether cryosurgery or cryoablation will prove a viable alternative to lumpectomy — the standard of care for women with early breast cancer — remains uncertain.
In Search of the Right Treatment Combinations for Multiple Myeloma
A pooled analysis of 3 combination drug regimens used to treat refractory/relapsed multiple myeloma reaffirms their safety, but does little to distinguish which approach works best.
Pembrolizumab Is Promising for Future Merkel Cell Cancer Treatment
For Merkel-cell cancers—the deadliest and rarest type—there are no approved drugs once surgery and radiation fail.
FDA Approves First-ever Blood Test for Colon Cancer Screening, Despite Split Opinion
Physicians and cancer organizations suggest more research is needed before the Epi proColon blood test becomes a standard screening approach.
FDA Approves Second Biosimilar Since Releasing Labeling Guidance, Despite Patent Protection, Safety Concerns
Ongoing litigation over patent protection and concern about drug labeling guidance and potential safety issues have slowed the availability of biosimilars.
- Loading...
Loading...
Next post in Supportive Care
Loading... 
Loading...